These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 11484509

  • 1. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
    Adachi T, Oda Y, Sakamoto A, Saito T, Tamiya S, Masuda K, Tsuneyoshi M.
    Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
    [Abstract] [Full Text] [Related]

  • 2. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S, Della Torre G, Lavarino C, Di Palma S, Sozzi G, Minoletti F, Rao S, Pasquini G, Azzarelli A, Rilke F, Pierotti MA.
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [Abstract] [Full Text] [Related]

  • 3. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
    Jing W, Lan T, Chen H, Zhang Z, Chen M, Peng R, He X, Zhang H.
    Histopathology; 2018 Jun; 72(7):1145-1155. PubMed ID: 29368794
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
    Thway K, Flora R, Shah C, Olmos D, Fisher C.
    Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
    [Abstract] [Full Text] [Related]

  • 5. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma.
    Dei Tos AP, Doglioni C, Piccinin S, Maestro R, Mentzel T, Barbareschi M, Boiocchi M, Fletcher CD.
    J Pathol; 1997 Jan; 181(1):8-13. PubMed ID: 9071997
    [Abstract] [Full Text] [Related]

  • 6. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M.
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [Abstract] [Full Text] [Related]

  • 7. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.
    Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B, Azzarelli A, Rilke F, Pierotti MA.
    J Pathol; 1998 Jun; 185(2):188-90. PubMed ID: 9713346
    [Abstract] [Full Text] [Related]

  • 8. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
    Lee SE, Kim YJ, Kwon MJ, Choi DI, Lee J, Cho J, Seo SW, Kim SJ, Shin YK, Choi YL.
    Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
    [Abstract] [Full Text] [Related]

  • 9. p53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer.
    Veloso M, Wrba F, Kaserer K, Heinze G, Magalhães A, Herbst F, Teleky B.
    Virchows Arch; 2000 Sep; 437(3):241-7. PubMed ID: 11037343
    [Abstract] [Full Text] [Related]

  • 10. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
    Butò S, Pierotti MA, Tamborini E, Della Torre G, Lavarino C, Rilke F, Pilotti S.
    Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
    [Abstract] [Full Text] [Related]

  • 11. Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma.
    Ishii T, Kohashi K, Ootsuka H, Iura K, Maekawa A, Yamada Y, Bekki H, Yoshimoto M, Yamamoto H, Iwamoto Y, Oda Y.
    Pathol Res Pract; 2017 Jun; 213(6):634-638. PubMed ID: 28552535
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical, cytogenetic, and molecular cytogenetic characterization of both components of a dedifferentiated liposarcoma: implications for histogenesis.
    Nishio J, Iwasaki H, Nabeshima K, Naito M.
    Anticancer Res; 2015 Jan; 35(1):345-50. PubMed ID: 25550570
    [Abstract] [Full Text] [Related]

  • 13. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
    Boltze C, Schneider-Stock R, Jäger V, Roessner A.
    Pathol Res Pract; 2001 Jan; 197(8):563-8. PubMed ID: 11518050
    [Abstract] [Full Text] [Related]

  • 14. Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.
    Jing W, Lan T, Qiu Y, Peng R, Lu Y, Chen H, Chen M, He X, Chen C, Zhang H.
    Diagn Pathol; 2021 Oct 25; 16(1):96. PubMed ID: 34696768
    [Abstract] [Full Text] [Related]

  • 15. Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations.
    Dowell SP, McGoogan E, Picksley SM, el-Deiry WS, Vogelstein B, Hall PA.
    Cytopathology; 1996 Oct 25; 7(5):340-51. PubMed ID: 8911758
    [Abstract] [Full Text] [Related]

  • 16. Expression of MDM2 and p16 in angiomyolipoma.
    Lin X, Laskin WB, Lu X, Zhang Y.
    Hum Pathol; 2018 May 25; 75():34-40. PubMed ID: 29432785
    [Abstract] [Full Text] [Related]

  • 17. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
    Wang X, Asmann YW, Erickson-Johnson MR, Oliveira JL, Zhang H, Moura RD, Lazar AJ, Lev D, Bill K, Lloyd RV, Yaszemski MJ, Maran A, Oliveira AM.
    Genes Chromosomes Cancer; 2011 Nov 25; 50(11):849-58. PubMed ID: 21793095
    [Abstract] [Full Text] [Related]

  • 18. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P, Bartkowiak JK, Szadowska AM, Olborski B, Harezga-Bal B, Debiec-Rychter M.
    J Exp Clin Cancer Res; 1999 Sep 25; 18(3):403-16. PubMed ID: 10606188
    [Abstract] [Full Text] [Related]

  • 19. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K, Oda Y, Sakamoto A, Saito T, Tamiya S, Iwamoto Y, Tsuneyoshi M.
    Mod Pathol; 2002 Aug 25; 15(8):878-88. PubMed ID: 12181274
    [Abstract] [Full Text] [Related]

  • 20. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R, Pezzella F, Gatter K, Algara P, Sánchez-Beato M, Martínez P, Martínez JC, Muñoz K, García P, Sánchez L, Kocialkowsky S, Campo E, Orradre JL, Piris MA.
    J Pathol; 1997 Jan 25; 181(1):51-61. PubMed ID: 9072003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.